DNAprint Genomics (DNAG)

[sam1933]

This analytical paper was submitted for discussion at the Workshop on Policy Issues in the Development and Use of Biomarkers in Health held on 6-7 October 2008 in Hinxton, United Kingdom. It is submitted for information to the WPB.

DIRECTORATE FOR SCIENCE, TECHNOLOGY AND INDUSTRY
COMMITTEE FOR SCIENTIFIC AND TECHNOLOGICAL POLICY
10-Nov-2008

Biomarkers will constitute a critical component of the health care delivery system in order to detect, diagnose and monitor diseases and other medical conditions as well as to evaluate treatment options and effectiveness. Interest in such techniques is growing rapidly among regulators and contract research organizations. However, scientific and commercial hurdles remain.

http://www.olis.oecd.org/olis/2008doc.nsf/ENGDATCORPLOOK/NT00005F12/$FILE/JT03254956.PDF


Table 1 – Publicly listed companies with commercial interest in biomarkers
(As of May 30, 2008)